Back to News
Market Impact: 0.2
Here's Why Sutro Biopharma (STRO) is Poised for a Turnaround After Losing 34.2% in 4 Weeks
Source: zacks.com
Healthcare & BiotechAnalyst EstimatesMarket Technicals & FlowsAnalyst Insights
Sutro Biopharma (STRO) is described as technically oversold after heavy selling, while analysts have broadly revised earnings estimates higher. The article suggests these factors could support a trend reversal, but provides no estimate figures or evidence that a reversal has occurred.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
STRO0.45
More News
- What Wall Street billionaires are saying about Democrats' midterm sweep
- NextDC shares surge 43% after Goodman, Digital Realty stake purchases
- A blue wave sends futures into the green
- Oil and data centre stocks sink after US midterms
- ‘Seismic’ blue wave triggers the sinking of oil prices, energy stocks, and the chances of power permitting reform
- Oil Price Forecast: WTI and Brent Plunge After US Midterm Elections